EGFR and cancer: Activating mutations in the epidermal growth factor receptor (EGFR) gene occur as early cancer-driving clonal event (2) in a subset of NSCLC patients (approximately 15% of Caucasian patients) and predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs) (3).